Login to Your Account



Other News To Note


Friday, March 2, 2012
• AtheroNova Inc., of Irvine, Calif., initiated the first shipment of AHRO-001 active pharmaceutical ingredient to R&D partner CardioNova Ltd., a Russian subsidiary of Maxwell Biotech Group, for Phase I and II studies in AHRO-001's initial application in the treatment and prevention of atherosclerosis. AHRO-001 uses natural compounds to reduce atherosclerotic plaque deposits through delipidization, which dissolves plaques in artery walls and enables them to be removed by natural body processes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription